Ionis Pharmaceuticals
IONS
238 hedge funds and large institutions have $3.58B invested in Ionis Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 84 increasing their positions, 80 reducing their positions, and 41 closing their positions.
15% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 41
2% more funds holding
Funds holding: 234 → 238 (+4)
5% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 80
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
21% less capital invested
Capital invested by funds: $4.52B → $3.58B (-$944M)
34% less call options, than puts
Call options by funds: $63.4M | Put options by funds: $95.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
+$28.2M |
| 2 |
GTP
Global Thematic Partners
New York
|
+$27M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$23.7M |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$18.9M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$38.1M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$37.5M |
| 3 |
CCI
Columbus Circle Investors
|
-$31.8M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$29.7M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$18.5M |
IONS Hedge Fund Activity: Q2 2014 in Review
238 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2014, worth a combined $3.58B — down 21% from $4.52B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new IONS positions and 41 closed out — a net gain of 6 holders — while 84 added to existing stakes and 80 trimmed.
The largest buyer was ClearBridge Investments, adding an estimated $28.2M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $38.1M sold.
- 238 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2014, up from 234 in Q1 2014.
- Funds reported $3.58B of Ionis Pharmaceuticals stock for Q2 2014, down 21% quarter-over-quarter.
- 47 funds opened new Ionis Pharmaceuticals positions in Q2 2014 and 41 closed out, a net change of +6 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2014 was ClearBridge Investments, an estimated $28.2M added.
- The largest Ionis Pharmaceuticals seller in Q2 2014 was Sectoral Asset Management, an estimated $38.1M sold.
Based on aggregated 13F filings for Q2 2014.